News
MOLN
4.100
0.00%
0.000
Weekly Report: what happened at MOLN last week (0427-0501)?
Weekly Report · 6d ago
Molecular Partners presents MP0712 data at upcoming scientific conferences
PUBT · 6d ago
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Barchart · 6d ago
Molecular Partners publishes MP0317 clinical data in Nature Cancer
TipRanks · 05/01 11:32
Molecular Partners Announces Publication Of Phase 1 Clinical Data In 'Nature Cancer' That Illustrate The Potential Of Tumor-Localized CD40 Agonist, MP0317, To Modulate The Tumor Microenvironment
Benzinga · 05/01 11:08
MOLECULAR PARTNERS AG - MP0317 SHOWED FAVORABLE SAFETY UP TO HIGHEST DOSE AND SUITABILITY FOR WEEKLY OR THREE-WEEK DOSING
Reuters · 05/01 11:00
MOLECULAR PARTNERS PUBLISHES PHASE 1 MP0317 DATA IN NATURE CANCER DEMONSTRATING TUMOR-LOCALIZED CD40 ACTIVATION AND TUMOR MICROENVIRONMENT REMODELING
Reuters · 05/01 11:00
Molecular Partners publishes Phase 1 MP0317 data showing tumor-localized CD40 activation
PUBT · 05/01 11:00
Weekly Report: what happened at MOLN last week (0420-0424)?
Weekly Report · 04/27 09:59
HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target
Benzinga · 04/22 11:51
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
TipRanks · 04/22 10:25
Molecular Partners shareholders approved CHF 1.13 million board pay cap for next term
PUBT · 04/20 13:13
Weekly Report: what happened at MOLN last week (0413-0417)?
Weekly Report · 04/20 09:56
Reported Sunday, Molecular Partners Nominates MP0632 As First Logic-Gated Switch-DARPin T Cell Engager Candidate For MSLN/EpCAM-Expressing Solid Tumors With Favorable Therapeutic Window At AACR 2026
Benzinga · 04/20 08:40
Molecular Partners announces presentation of preclinical data at AACR
TipRanks · 04/19 16:55
Molecular Partners’ MP0712 advances in ongoing US Phase 1/2a DLL3 cancer trial
PUBT · 04/19 16:00
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Barchart · 04/19 11:00
Molecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals
TipRanks · 04/14 21:23
Molecular Partners elects Clare Fisher to board of directors at AGM
PUBT · 04/14 20:00
MOLECULAR PARTNERS ANNOUNCES ALL BOARD PROPOSALS APPROVED, CLARE FISHER ELECTED AS NEW BOARD MEMBER AT ANNUAL GENERAL MEETING
Reuters · 04/14 20:00
More
Webull provides a variety of real-time MOLN stock news. You can receive the latest news about MOLECULAR PARTNERS AG through multiple platforms. This information may help you make smarter investment decisions.
About MOLN
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.